Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Circular Genomics Unveils MindLight™: The First SSRI Antidepressant Response Test Based on Brain-Derived Biomarkers

NextEdge Admin

18 Sep 2024

2 min 8 sec

Circular Genomics, a global leader in circular RNA biomarkers for precision psychiatry and neurology, has launched MindLight, the first circular RNA biomarker-based test designed to predict whether a patient with major depressive disorder will respond to selective serotonin reuptake inhibitor (SSRI) antidepressants. This innovative test aims to streamline treatment for depression by providing personalized insights into SSRI response, offering a new standard in precision psychiatry.

"Currently, depression treatment often involves trial and error with medications, leading to delays in effective care. While SSRIs are the most commonly prescribed antidepressants, less than half of patients respond positively," said Paul Sargeant, PhD, CEO of Circular Genomics. "MindLight uses a biomarker-based approach to help doctors quickly determine if SSRIs will be effective, allowing for a personalized treatment plan within a week."

Clinical data shows that only 41% of patients respond to SSRIs, while the rest may benefit from alternative treatments. MindLight leverages brain-derived circular RNA biomarkers, detectable in the blood, to predict SSRI response with 77% accuracy. Patients identified as "High Likelihood of Response" are 3.4 times more likely to benefit from SSRIs compared to those categorized as "Low Likelihood of Response."

MindLight is a simple blood test ordered by physicians, with results returned in 3-5 days, offering clear and actionable insights to guide personalized treatment decisions.